Bio-Techne (TECH) Other financing activities (2009 - 2022)
Bio-Techne's quarterly Other financing activities came in at -$2.5 million in Q3 2022, down 113.43% year-on-year from $18.3 million in Q3 2021, and down 172.26% quarter-over-quarter from $3.4 million in Q1 2022.
Bio-Techne has reported Other financing activities for 14 years, with the latest figure at -$2.5 million in Q3 2022.
- For the quarter ending Q3 2022, Other financing activities fell 113.43% year-over-year to -$2.5 million; the trailing twelve-month figure through Jun 2023 stood at -$2.5 million (down 108.84% YoY), and the FY2023 full-year result was -$2.5 million, down 411.8% from the prior year.
- Other financing activities for Q3 2022 stood at -$2.5 million, down from $3.4 million in the prior quarter.
- The five-year high for Other financing activities was $41.6 million in Q2 2021, with the low at -$11.1 million in Q2 2019.
- Average Other financing activities over 5 years is $5.3 million, with a median of $3.4 million recorded in 2018.
- Peak annual rise in Other financing activities reached 1133.33% in 2019, while the deepest fall reached 3234.75% in 2019.
- Tracing TECH's Other financing activities over 5 years: stood at $300000.0 in 2018, then soared by 1133.33% to $3.7 million in 2019, then gained by 29.73% to $4.8 million in 2020, then climbed by 27.08% to $6.1 million in 2021, then slumped by 140.28% to -$2.5 million in 2022.
- The last three Other financing activities figures came in at -$2.5 million (Q3 2022), $3.4 million (Q1 2022), and $6.1 million (Q4 2021), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Bio-Techne | 7.92 Bn | 7.71 Bn | 208.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -2.46 Mn |
| Sep 30, 2022 | -2.46 Mn |
| Mar 31, 2022 | 3.40 Mn |
| Mar 31, 2022 | 3.40 Mn |
| Dec 31, 2021 | 6.10 Mn |
| Dec 31, 2021 | 6.10 Mn |
| Sep 30, 2021 | 18.30 Mn |
| Sep 30, 2021 | 18.30 Mn |
| Jun 30, 2021 | 41.60 Mn |
| Jun 30, 2021 | 41.60 Mn |
| Mar 31, 2021 | 11.70 Mn |
| Mar 31, 2021 | 11.70 Mn |
| Dec 31, 2020 | 4.80 Mn |
| Dec 31, 2020 | 4.80 Mn |
| Sep 30, 2020 | 3.30 Mn |
| Sep 30, 2020 | 3.30 Mn |
| Jun 30, 2020 | 9.20 Mn |
| Jun 30, 2020 | 9.20 Mn |
| Mar 31, 2020 | 1.50 Mn |
| Mar 31, 2020 | 1.50 Mn |
| Dec 31, 2019 | 3.70 Mn |
| Dec 31, 2019 | 3.70 Mn |
| Sep 30, 2019 | 3.20 Mn |
| Sep 30, 2019 | 3.20 Mn |
| Jun 30, 2019 | -11.10 Mn |
| Jun 30, 2019 | -11.10 Mn |
| Mar 31, 2019 | 1.10 Mn |
| Mar 31, 2019 | 1.10 Mn |
| Dec 31, 2018 | 300,000.00 |
| Dec 31, 2018 | 300,000.00 |
| Sep 30, 2018 | 3.40 Mn |
| Sep 30, 2018 | 3.40 Mn |
| Jun 30, 2018 | 354,000.00 |
| Jun 30, 2018 | 354,000.00 |
| Mar 31, 2018 | -2.18 Mn |
| Mar 31, 2018 | -2.18 Mn |
| Dec 31, 2017 | -355,000.00 |
| Dec 31, 2017 | -355,000.00 |
| Sep 30, 2017 | -1.80 Mn |
| Sep 30, 2017 | -1.80 Mn |
| Jun 30, 2017 | 771,000.00 |
| Jun 30, 2017 | 771,000.00 |
| Mar 31, 2017 | -86,000.00 |
| Mar 31, 2017 | -86,000.00 |
| Dec 31, 2016 | 82,000.00 |
| Dec 31, 2016 | 82,000.00 |
| Sep 30, 2016 | -253,000.00 |
| Sep 30, 2016 | -253,000.00 |
| Jun 30, 2016 | -327,000.00 |
| Jun 30, 2016 | -327,000.00 |
| Mar 31, 2016 | -119,000.00 |
| Mar 31, 2016 | -119,000.00 |
| Dec 31, 2015 | 11,000.00 |
| Dec 31, 2015 | 11,000.00 |
| Sep 30, 2015 | -131,000.00 |
| Sep 30, 2015 | -131,000.00 |
| Jun 30, 2015 | -1.01 Mn |
| Jun 30, 2015 | -1.01 Mn |
| Mar 31, 2015 | 134,000.00 |
| Mar 31, 2015 | 134,000.00 |
| Dec 31, 2014 | 180,000.00 |
| Dec 31, 2014 | 180,000.00 |
| Sep 30, 2014 | 78,000.00 |
| Sep 30, 2014 | 78,000.00 |
| Jun 30, 2014 | 262,000.00 |
| Jun 30, 2014 | 262,000.00 |
| Mar 31, 2014 | -40,000.00 |
| Mar 31, 2014 | -40,000.00 |
| Dec 31, 2013 | 36,000.00 |
| Dec 31, 2013 | 36,000.00 |
| Sep 30, 2013 | 4,000.00 |
| Sep 30, 2013 | 4,000.00 |
| Jun 30, 2013 | 6,000.00 |
| Jun 30, 2013 | 6,000.00 |
| Mar 31, 2013 | 5,000.00 |
| Mar 31, 2013 | 5,000.00 |
| Dec 31, 2012 | 63,000.00 |
| Dec 31, 2012 | 63,000.00 |
| Sep 30, 2012 | 1,000.00 |
| Sep 30, 2012 | 1,000.00 |
| Mar 31, 2012 | 38,000.00 |
| Mar 31, 2012 | 38,000.00 |
| Dec 31, 2011 | 6,000.00 |
| Dec 31, 2011 | 6,000.00 |
| Sep 30, 2011 | 7,000.00 |
| Sep 30, 2011 | 7,000.00 |
| Jun 30, 2011 | 428,000.00 |
| Jun 30, 2011 | 428,000.00 |
| Mar 31, 2011 | 6,000.00 |
| Mar 31, 2011 | 6,000.00 |
| Dec 31, 2010 | 330,000.00 |
| Dec 31, 2010 | 330,000.00 |
| Sep 30, 2010 | 83,000.00 |
| Sep 30, 2010 | 83,000.00 |
| Jun 30, 2010 | 19,000.00 |
| Jun 30, 2010 | 19,000.00 |
| Mar 31, 2010 | 126,000.00 |
| Mar 31, 2010 | 126,000.00 |
| Dec 31, 2009 | 41,000.00 |
| Dec 31, 2009 | 41,000.00 |
| Sep 30, 2009 | 10,000.00 |
| Sep 30, 2009 | 10,000.00 |